导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.96% | 1620/4773 |
| 近一周 | -0.83% | 1902/5467 |
| 近一月 | -6.39% | 3100/5421 |
| 近一季 | -10.83% | 3394/5238 |
| 近半年 | -3.95% | 2837/4931 |
| 近一年 | 5.96% | 1456/4400 |
| 近两年 | 73.15% | 945/2954 |
| 近三年 | 37.15% | 825/2253 |
| 成立以来 | 158.66% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.89% 1145/4961 |
18.51% 1372/5312 |
- - |
- - |
| 2025 | 31.16% 1261/4813 |
2.10% 1467/3635 |
1.73% 2193/4076 |
25.26% 1409/4524 |
0.81% 1751/4813 |
| 2024 | 6.97% 1703/3463 |
-2.69% 1410/2808 |
-5.36% 1703/3014 |
16.35% 1478/3129 |
-0.17% 1335/3463 |
| 2023 | -6.69% 870/2656 |
7.94% 511/2280 |
-4.47% 1185/2385 |
-4.91% 1253/2515 |
-4.83% 1187/2655 |
| 2022 | -18.75% 748/2207 |
-14.08% 901/1919 |
3.19% 1197/2016 |
-10.77% 449/2113 |
2.72% 853/2208 |
| 2021 | 16.86% 256/1822 |
-1.78% 541/1255 |
10.06% 494/1330 |
4.64% 329/1466 |
3.31% 452/1822 |
| 2020 | 28.65% 557/1250 |
-4.02% 335/1028 |
16.89% 404/1067 |
10.30% 562/1164 |
3.96% 882/1184 |
| 2019 | 27.44% 546/1092 |
32.75% 167/754 |
-9.84% 694/804 |
0.30% 533/850 |
6.15% 649/918 |
| 2018 | -30.88% 481/834 |
- - |
- - |
- - |
-12.68% 471/691 |
| 2017 | 2.25% 442/714 |
- - |
- - |
- - |
- - |
| 2016 | -17.82% 401/605 |
- - |
- - |
- - |
- - |
| 2015 | 42.24% 39/575 |
- - |
- - |
- - |
- - |
| 2014 | 39.97% 125/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 景顺长城中证500ETF VS. 长安沪深300非周期A(740101) |